Lavender's Game: Silexan For Anxiety

A structured deep dive on silexan (a branded lavender-oil extract) for anxiety, prompted by unusually strong endorsements (a Carlat Report calling it a large-effect-size exception among alternative treatments, alongside stimulants and ketamine). The claims would change the world if true -- works better than benzos, no addiction, no major side effects. The central catch: the four supporting meta-analyses draw on only six studies, five of them by the same researcher (Kasper), all funded by or connected to the manufacturer (Schwabe). Scott contextualizes this as par-for-the-course in supplements/psychopharm rather than disqualifying, and finds the actual studies well-done (Kasper 2014: n=539, double-blind with lavender-scented placebo, p<0.001, effect size 0.37-0.5, beating paroxetine). Surveys circumstantial evidence (animal studies, mixed personal/nootropics anecdotes, the aromatherapy/olfactory-mechanism debate), gives practical guidance (160mg of the studied brand; the lavender-burp side effect that might be part of the mechanism; no addiction risk), and lands on a default 'yes, try it -- $12, low risk' plus a 50% prediction that independent studies will show an effect size >= SSRIs.

Quality 71 · Strong. Strong. A clear, balanced, practically-useful drug review -- honest about the single-researcher/industry-funding problem without overcorrecting, and with concrete prescribing guidance and a registered prediction. Mid-Strong as a competent evidence review of one supplement.

Claude’s paradigm shift 44 · Moderate. Moderate. A careful evidence review; minimal novelty.

Real-world impact 2 · Minor. Minor. Within the psychopharm/nootropics discourse with modest prescribing guidance; conceptual. 2.